ID: MRFR/HC/5127-HCR | 85 Pages | Published By Kinjoll Dey on March 2023
The Sacroiliitis Treatment Market is anticipated to reach USD 142.15 Billion by 2030 at 18.40% CAGR during the forecast period 2022-2030.
The sacroiliac joint also known as SI joint is the joint situated between the sacrum and the ilium bones of the pelvis, which is coupled by strong ligaments. In case of human being, the sacrum supports the spine and is supported in turn by an ilium on each side. The sacroiliitis is an inflammation of either one or both of sacroiliac joint. Sacroiliitis causes pain in the buttocks or lower back and can extend down one or both legs. Prolonged standing or stair climbing can increase the pain.
Numerous technological innovations in the devices along with an expanding profile of joint disorders foster the growth of the market. Increasing incidences and prevalence of joint disorders, growing awareness among the population, increase in initiatives by government organizations and investment by private companies for research and development, rising elderly population all contributes to the growth of the sacroiliitis treatment market. Though currently available therapeutic options are effective at managing and preventing joint disease progression, the challenges of treating the joint diseases lie in the unpredictable responses of each patient, representing one of the biggest unmet needs in the global sacroiliitis treatment market.
The global sacroiliitis treatment market has been segmented on the basis of type and end users.
On the basis of type, the market has been classified as medications, joint injections, radiofrequency denervation, electrical stimulation, joint fusion. The medications are segmented into pain relievers, muscle relaxants, and TNF inhibitors.
On the basis of end users, the market has been classified as hospitals, clinics, ambulatory care, home care, diagnostic centers, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European sacroiliitis treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The sacroiliitis treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The sacroiliitis treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Sacroiliitis Treatment Market Share, by Region, 2017 (%)
Source: MRFR Analysis
In the sacroiliitis treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures. According to a 2014 study shared by the US National Library of Medicine, approximately 19 to 29% of adults in the US are suffering from lower back pain and sacroiliitis joints. Patients who deal with chronic lower back pain spend about twice as much money on health-related expenses each year.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to the increasing number of surgeries and the increasing demand for advanced treatment procedures are boosting the European market.
The Asia-Pacific market is expected to be the fastest growing segment in the near future because of the high rate of development in the healthcare industry, increasing prospects for the new marketer and rising government activity for the control of joint disorders. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region.
The market in the Middle East and Africa is expected to account for the smallest share of the global sacroiliitis treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Some of the key players in the global sacroiliitis treatment market are Pfizer, Allergan, Ipsen Group, Teva Pharmaceuticals, Novartis, Johnson & Johnson, STEROID S.p.A., Sanofi, Bioventus, Salix Pharmaceuticals, Zimmer Holdings, Inc., Smith & Nephew Plc, and others.
Global Sacroiliitis Treatment Market, by Type
Global Sacroiliitis Treatment Market, by End-Users
Global Sacroiliitis Treatment Market, by Region